tbuckley/cabot-search huggingface dataset:
Women with cancer undergoing IVF for fertility preservation: A case-control study of response to exogenous gonadotropins
Authors: J. M. Knopman, N. Noyes, S. Talebian, E. Fino, L. Krey, J. P. Curtin, J. A. Grifo, F. Licciardi
Journal: Journal of Clinical Oncology (2008)

9582 Background: Early detection programs and advancements in treatment allow women with cancer to live longer lives making quality of life issues, such as preserving fertility important. Review of the male literature has shown that malignancy adversely affects fertility, even prior to the initiation of cancer treatment. Whether the presence of cancer in female patients affects ovarian response to gonadotropin hyperstimulation has not been examined. The objective of this study was to determine if women with cancer, pre-treatment, show a decreased response to ovarian hyperstimulation. We originally presented data on the first 17 patients; this abstract represents an update incorporating a total of 28 women with cancer. Methods: From 2001 to 2006, 28 patients diagnosed with cancer presented seeking fertility preservation. Prior to fertility treatment, day 2 estradiol and FSH levels were assessed. 27 of the patients were hyperstimulated with GnRH antagonist protocols; 1 patient received leuprolide down-regulation prior to hyperstimulation. HCG injection was administered when the lead follicle(s) were ≥ 17 mm and oocyte retrieval was performed 36 hours later. Serum estradiol levels were assessed on the day of hCG administration. Oocytes were harvested in routine fashion and all mature eggs were either cryopreserved as unfertilized gametes or fertilized. Results: The mean age of the cancer patients was 34 ± 5 (20 - 41) years. Serum estradiol levels on the day of hCG administration for cancer patients, 1515 +712 pg/ml was lower than those noted in controls 1852 + 021 pg/ml; p< 0.05. There was no difference in number of oocytes retrieved when comparing all cancer patients to all controls (14 + 9, and 14 + 7, respectively), but younger cancer patients had more (18 ± 9) oocytes retrieved than the older study counterpart (11 ± 9; p=0.03). Conclusions: Cancer patients produce a similar number of oocytes following ovarian hyperstimulation when compared to age-matched infertile controls suggesting that malignancy, itself, does not adversely affect ovarian reserve. However, estradiol levels were significantly lower in women with malignancy. In addition, similar to the general IVF population, age appears to be the primary determinant of oocyte quantity in cancer patients. No significant financial relationships to disclose.
Ruxolitinib Therapy Effectively Modulates CD34+ Hematopoietic Progenitors and Bone Marrow Angiogenesis in Patients with Myelofibrosis
Authors: Hans Michael Kvasnicka, Juergen Thiele, Carlos E. Bueso-Ramos, Shilpa Kamalanabhaiah, Jorge E. Cortes, Hagop M. Kantarjian, Srdan Verstovsek
Journal: Blood (2014)
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
Authors: Charles Peterfy, Gerd R Burmester, Vivian P Bykerk, Bernard G Combe, Julie C DiCarlo, Daniel E Furst, Tom W J Huizinga, Dennis A Wong, Philip G Conaghan, Paul Emery
Journal: Annals of the Rheumatic Diseases (2016)

To assess structural damage progression with subcutaneous abatacept (ABA) in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial following abrupt withdrawal of all rheumatoid arthritis (RA) medication in patients achieving Disease Activity Score (DAS)-defined remission or low disease activity.Patients with early, active RA were randomised to ABA plus methotrexate (ABA/MTX) 125 mg/week, ABA 125 mg/week or MTX for 12 months. All RA treatments were withdrawn after 12 months in patients with DAS28 (C reactive protein (CRP)) <3.2. Adjusted mean changes from baseline in MRI-based synovitis, osteitis and erosion were calculated for the intention-to-treat population.351 patients were randomised and treated: ABA/MTX (n=119), ABA (n=116) or MTX (n=116). Synovitis and osteitis improved, and progression of erosion was statistically less with ABA/MTX versus MTX at month 12 (-2.35 vs -0.68, -2.58 vs -0.68, 0.19 vs 1.53, respectively; p<0.01 for each) and month 18 (-1.34 vs -0.49 -2.03 vs 0.34, 0.13 vs 2.0, respectively; p<0.01 for erosion); ABA benefits were numerically intermediate to those for ABA/MTX and MTX.Structural benefits with ABA/MTX or ABA may be maintained 6 months after withdrawal of all treatments in patients who have achieved remission or low disease activity.NCT01142726; Results.
Preliminary results from two phase II studies of lenalidomide monotherapy in relapsed/refractory non-Hodgkin’s Lymphoma
Authors: P. H. Wiernik, I. S. Lossos, G. Justice, J. B. Zeldis, K. Takeshita, D. Pietronigro, T. M. Habermann, T. E. Witzig
Journal: Journal of Clinical Oncology (2006)

17569 Background: Lenalidomide is an immunomodulatory drug of the IMiD class that has activity in multiple myeloma, myelodysplastic syndromes and chronic lymphocytic leukemia. We report preliminary results of two Phase II studies assessing the safety and efficacy of lenalidomide monotherapy in subjects with relapsed/refractory indolent or aggressive non-Hodgkin’s lymphoma (NHL). Methods: Subjects with indolent (study NHL-001) or aggressive (study NHL-002) relapsed/refractory NHL following ≥ 1 prior treatment regimen with measurable disease are eligible. Subjects receive 25 mg lenalidomide orally once daily on Days 1–21 every 28 days and continue therapy for 52 weeks as tolerated until disease progression. Response and progression are evaluated using cross sectional imaging by the NCI criteria. Results: 10 subjects (2 indolent (I), 8 aggressive (A)) of a planned 80 (40 in each study) have enrolled thus far. Median age is 66 (45–80) and 7 subjects are female. Indolent histology is follicular center lymphoma grade 1, 2 (n = 2) and aggressive histology diffuse large cell lymphoma (n = 7) and follicular center lymphoma grade 3 (n = 1). Median time from diagnosis to lenalidomide monotherapy is 2.9 years (1.1–10) and median number of prior treatment regimens per subject is 3 (1–6). Median duration of follow-up is 2 months. Of eight subjects (2 I, 6 A) evaluable for response at two months, three demonstrated a decrease in their tumor burden by 72% (I), 68% (A) and 52% (A), two subjects (2 A) exhibited stable disease and three subjects (1 I, 2 A) had disease progression. Six of the ten subjects (2 I, 4 A) demonstrated no Grade 3 or 4 adverse events. Grade 3 or 4 hematological adverse events (neutropenia, thrombocytopenia) occurred in four subjects including one febrile neutropenia and one of these four subjects also exhibited Grade 3 cellulitis. No tumor flare or tumor lysis has been observed to date. Conclusions: Preliminary data of lenalidomide monotherapy in relapsed and refractory NHL are encouraging. [Table: see text]
Neoadjuvant chemotherapy in second trimester pregnant patients with cervical cancer: First study on in vivo concentrations of cisplatinum in fetal and maternal compartments.
Authors: S. Marnitz, A. H. Schmittel, K. Hasenbein, G. Favero, A. Schneider, C. Kóhler
Journal: Journal of Clinical Oncology (2010)

5104 Background: Cervical cancer in the second trimester of pregnancy is rare but decision for termination or delay of pregnancy is always a challenge and multidisciplinary cooperation and consultation is mandatory. Platinum-based chemotherapy is recommended to prevent cancer progression during waiting time for fetal maturity but knowledge about passage of platinum through placenta is very limited. Methods: Between 5/2008 and 1/2010 six consecutive patients with cervical cancer diagnosed in second trimester underwent (re-)conisation and/or pelvic laparoscopic lymphadenectomy. In consent with the patients delay of pregnancy in combination with neoadjuvant chemotherapy was performed because of local residual tumor, high-risk situation or advanced disease. After 3 cycles (one patient 2) of cisplatin chemotherapy caesarean section together with radical (1× simple) hysterectomy was performed not less than 32 week of gestation. At the time of delivery synchronous samples from maternal blood, umbilical cord blood and amnion fluid were taken and analysed for cisplatinum concentration. Results: Laparoscopic pelvic lymphadenectomy was uncomplicated in all patients with a mean blood loss of 60 (20-120) cc. In 5/6 patients lymph nodeswere tumour free. Healthy babies without renal, hepatic, auditory or haematopoietic impairment were delivered in all patients. Cisplatin concentrations in the umbilical cord and amnion fluid were 50%-60% and 20%-40% of the maternal blood. Conclusions: This is the first case series analysing quantitative platinum concentrations in maternal and fetal compartment after neoadjuvant chemotherapy in cervical cancer patients. The knowledge of relevant lower cisplatin concentrations in umbilical cord and amnion fluid overcomes prejudices and concerns about neoadjuvant chemotherapy to delay second trimester pregnancy in patients with cervical cancer. No significant financial relationships to disclose.
DNA repair inhibition by DT01 as an adjuvant therapy at each stage of hepatocellular cancer (HCC) treatment.
Authors: Flavien Devun, Nirmitha Herath, Alban Denys, Jian-sheng Sun, Marie Dutreix
Journal: Journal of Clinical Oncology (2015)

303 Background: Hepatocellular carcinoma (HCC) is the most common liver cancer. Radiofrequency ablation (RFA), transarterial chemoembolization (TACE) or chemotherapy (CT) can be considered at each stage of HCC. The efficacy of these DNA damage inducing treatments could be enhanced by DNA damage repair inhibition. DT01 inhibits the complete DNA double-strand break repair machinery. Here, we assess the combination of DT01 with RFA, TACE or CT in preclinical models. Methods: For association with RFA, mice bearing flank-grafted tumors were sham treated (n=18), treated by DT01 (n=22), RFA (n=21) or a combination of DT01 and RFA (n=19). Mice were either sacrificed for pathological study or followed for survival. For association with TACE, rabbits bearing VX2 hepatocellular carcinoma in liver were untreated (n=9), treated with TACE (n=13) or treated with TACE and DT01 (n=14). Tumor growth, vascularization, necrosis and metastases were assessed with ultrasound scanning, color Doppler, pathology and autopsy respectively. For association with CT, mice bearing orthotopic liver tumors were administered NaCl (n=7), CT (doxorubicin) (n=10), systemic DT01 treatment (n=7) or an association of DT01 and CT (n=10). Tumor growth and pathological studies were assessed. Results: Mice treated by RFA and DT01 have longer survival compared to RFA alone (median survival: 57 vs 40 days) with 54% of complete responses while RFA alone improved survival moderately (median survival: 40 vs 28 days for control). Rabbits treated with TACE and DT01, in comparison to CT alone, show efficient tumor growth control, an increase of tumor necrosis (61% vs 40%), a decrease of metastases (21 vs 54%) and an absence of neoangiogenesis rebound. Mice treated with CT in combination with DT01 show a significant decrease in tumor volume and tumor necrosis, compared to the mice treated with CT alone. In all models, DT01 addition to treatments did not add any toxicity. Conclusions: Our results show that the addition of DT01 to RFA, TACE or CT enhances their antitumor activities and provide an experimental basis for the use of DT01 as an adjuvant therapy at each stage of HCC treatment.
Smoking and Cancers of Bladder and Pancreas: Risks and Temporal Trends&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: S H Moolgavkar, R G Stevens
Journal: JNCI Journal of the National Cancer Institute (1981)

Mortality data from carcinomas of the pancreas (1941-75) and bladder (1941-70) in England and Wales were analyzed to study the association between cigarette smoking and these cancers. The analysis revealed that: a) The difference in male and female rates in these cancers is attributable to differences in smoking habits; b) the observed increase in mortality in these diseases is almost entirely due to a dramatic increase among smokers. The mortality rate among nonsmokers increased only slowly for carcinoma of the pancreas and actually fell for carcinoma of the bladder. This analysis, which is based on the total number of deaths in the population, yields estimates of relative risk associated with 20 pack-years of smoking of 1.6 and 3.0 for carcinomas of the pancreas and bladder, respectively. The proportion of deaths from carcinoma of the pancreas attributable to smoking increased from 25% in 1941-45 to 52% in 1971-75 in males and from 2 to 15% in females. The proportion of deaths from carcinoma of the bladder attributable to smoking increased form 53% in 1941-45 to 85% in 1966-70 in males and from 4 to 27% in females.
Prognostic markers for stage 3 neuroblastoma (NB): A report from the International Neuroblastoma Risk Group (INRG) project
Authors: J. R. Park, W. B. London, J. M. Maris, H. Shimada, Y. Zhang, K. K. Matthay, T. Monclair, P. F. Ambros, S. L. Cohn, A. Pearson
Journal: Journal of Clinical Oncology (2008)

10009 Background: There is lack of consensus on prognostic markers other than age and tumor MYCN amplification for children with INSS stage 3 NB. Methods: The INRG database (n=8800 patients) was utilized to assess whether age, elevated ferritin (≥ 96 ng/ml), tumor histology or somatically acquired chromosomes (ch) 1p or 11q aberrations impact EFS and OS from INSS stage 3, MYCN not amplified (NA) NB. Due to the confounding of Shimada histology with age, only tumor differentiation grade and MKI were tested in multivariate models. Results: Of 1,483 patients with INSS stage 3 tumors, 1,013 had MYCN-NA tumors. Among these, 654 (64.6%) patients were age <547 days (<18 months) at diagnosis. The 5-year EFS and OS rates for patients with INSS stage 3 MYCN-NA tumors were 81%±2% and 89%±1%, respectively. Age ≥18 months at diagnosis was associated with significantly decreased EFS and OS compared to age <18 months (EFS 64%±3% vs. 90%±2% p<0.0001; OS 76%±3% vs. 95%±1%, p<0.0001). For patients <18 months of age, tumor ch11q aberrations had a significantly inferior EFS (64%±22%) that remained independently prognostic in multivariate analysis (HR 5.3, p=0.0351). The presence of tumor ch11q aberrations or elevated serum ferritin was associated with a significantly worse OS (73%±22% and 88%±4%, respectively) but neither was independently prognostic in the multivariate model. For patients age ≥18 months, poorly/undifferentiated histology and elevated serum ferritin led to a significantly inferior EFS and OS but only ferritin was independently prognostic in multivariate analyses (EFS: HR 2.5, p=0.0319; OS: HR 2.7 p=0.0052). Conclusions: Patients <18 months of age at diagnosis of INSS Stage 3 MYCN-NA NB with somatically acquired ch11q aberrations are at significantly higher risk for relapse. In older patients, elevated serum ferritin or poorly/undifferentiated tumor histology significantly increase risk for recurrence. These biomarkers should be considered in treatment algorithms. No significant financial relationships to disclose.
Evolution of base composition in the insulin and insulin-like growth factor genes.
Authors: D L Ellsworth, D Hewett-Emmett, W H Li
Journal: Molecular Biology and Evolution (1994)

The genomes of homeothermic (warm-blooded) vertebrates are mosaic interspersions of homogeneously GC-rich and GC-poor regions (isochores). Evolution of genome compartmentalization and GC-rich isochores is hypothesized to reflect either selective advantages of an elevated GC content or chromosome location and mutational pressure associated with the timing of DNA replication in germ cells. To address the present controversy regarding the origins and maintenance of isochores in homeothermic vertebrates, newly obtained as well as published nucleotide sequences of the insulin and insulin-like growth factor (IGF) genes, members of a well-characterized gene family believed to have evolved by repeated duplication and divergence, were utilized to examine the evolution of base composition in nonconstrained (flanking) and weakly constrained (introns and fourfold degenerate sites) regions. A phylogeny derived from amino acid sequences supports a common evolutionary history for the insulin/IGF family genes. In cold-blooded vertebrates, insulin and the IGFs were similar in base composition. In contrast, insulin and IGF-II demonstrate dramatic increases in GC richness in mammals, but no such trend occurred in IGF-I. Base composition of the coding portions of the insulin and IGF genes across vertebrates correlated (r = 0.90) with that of the introns and flanking regions. The GC content of homologous introns differed dramatically between insulin/IGF-II and IGF-I genes in mammals but was similar to the GC level of noncoding regions in neighboring genes. Our findings suggest that the base composition of introns and flanking regions is determined by chromosomal location and the mutational pressure of the isochore in which the sequences are embedded. An elevated GC content at codon third positions in the insulin and the IGF genes may reflect selective constraints on the usage of synonymous codons.
Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study.
Authors: M. T. Milano, H. Li, M. H. Gail, L. S. Constine, L. B. Travis
Journal: Journal of Clinical Oncology (2010)

1502 Background: The markedly increased risk of BC among women receiving chest radiotherapy for HL is well established. However, no large, population-based studies exist that describe overall survival (OS) and cause-specific survival (CSS) compared to women with a first primary BC. Methods: For 298 HL survivors who developed BC (HL-BC patients) and 405,223 women with a first or only BC (BC-1 patients), actuarial OS and CSS were compared, accounting for age, BC stage, hormone receptor status, sociodemographic status, radiation for HL and other variables. All patients were derived from the population-based Surveillance, Epidemiology, and End Results program. Results: Compared with BC-1 patients, the HL-BC group was significantly younger at BC diagnosis (p < 0.0001), had a greater likelihood of high grade BC (p > 0.02), and greater likelihood of estrogen negative BC (p < 0.004) and progesterone receptor negative BC (p > 0.005 for localized BC and p > 0.06 for regional BC). HL-BC patients were > 1.5 times (p < 0.0001) more likely to undergo mastectomy (rather than breast conserving surgery) compared with BC-1 pts, and were > 2 times (p < 0.0001) less likely to have received radiation than BC-1 patients. Fifteen-year OS among HL-BC patients was significantly inferior to BC-1 patients: 48% versus 69% respectively (p<0.0001) for localized BC, and 33% versus 43% (p < 0.0001) for regional/distant BC. HL-BC patients had a significantly increased 7-fold risk (p < 0.0001) of death from other cancers (i.e., not HL or BC) compared to BC-1 patients. Mortality due to heart disease among HL-BC patients with either localized or regional/distant disease was also significantly increased (hazard ratio 2.22, p > 0.04; and hazard ratio 4.28, p > 0.02 respectively) compared to BC-1 patients. While 10-year BC CSS was similar for HL-BC and BC-1 patients with regional/distant disease, it was inferior for patients with localized BC (82% versus 88% respectively (p > 0.002). Conclusions: Women with HL may survive a subsequent diagnosis of BC only to experience significant excesses of death from other primary cancers and cardiac disease. Greater awareness of screening for cardiac disease and subsequent primary cancers in HL-BC patients is warranted. No significant financial relationships to disclose.
Antidepressant Prescription Claims Among Reproductive-Aged Women With Private Employer-Sponsored Insurance — United States 2008–2013
Authors: April L. Dawson, Elizabeth C. Ailes, Suzanne M. Gilboa, Regina M. Simeone, Jennifer N. Lind, Sherry L. Farr, Cheryl S. Broussard, Jennita Reefhuis, Gerrard Carrino, Janis Biermann, Margaret A. Honein
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Antidepressant medication use during pregnancy has been increasing in the United States (1). Many women require antidepressants on an ongoing basis, and a clear consensus on the safest medication options for both the mother and her fetus does not exist (2). Given that half of all U.S. pregnancies are unplanned (3), antidepressant use will occur during the first weeks of pregnancy, a critical period for fetal development. To understand trends among women of reproductive age, CDC used Truven Health's MarketScan Commercial Claims and Encounters data* to estimate the number of antidepressant prescriptions filled by women aged 15-44 years with private employer-sponsored insurance. During 2008-2013, an average of 15.4% of women aged 15-44 years filled at least one prescription for an antidepressant in a single year. The most frequently filled antidepressants included sertraline, bupropion, and citalopram. Prescribing of antidepressants is common, and research on antidepressant safety during pregnancy needs to be accelerated to provide evidence-based information to health care providers and women about the potential risks for antidepressant exposure before and during pregnancy and between pregnancies.
A survey of impulse control disorders in Parkinson’s disease patients in Shanghai area and literature review
Authors: Xue-Ping Wang, Ming Wei, Qin Xiao
Journal: Translational Neurodegeneration (2016)

Levodopa and dopamine agonists are the main treatments for Parkinson's disease (PD) in recent years. Increased drug dosages are linked to some severe side effects, one of which is impulse control disorders (ICD). Many studies have reported the related risk factors of ICDs, such as dopamine agonist, male sex, younger age, earlier age of onset and so on. This study aims to investigate the incidence of ICD in Chinese PD patients from Shanghai area, explore the association of ICD with dopamine replacement therapy (DRT). Two hundred seventeen PD patients were consecutively recruited from the Movement Disorder Clinic of Ruijin Hospital from March to October 2013. Minnesota Impulsive Disorders Interview was used to assess the PD patients. PD patients with possible ICD would undergo a further interview by a movement disorder specialist to confirm the diagnosis. Clinical information was also collected. Nine PD patients (4.15 %) showed ICD behaviors as follows: hypersexuality (4, 1.84 %), pathological gambling (3, 1.38 %), binge eating (1, 0.46 %), compulsive shopping (1, 0.46 %). Compared with the non-ICD PD group, ICD PD group took more dopamine agonists (LED 119.4 ± 86.4 mg/d vs 60.5 ± 80.5 mg/d, P = 0.019), had higher total levodopa equivalent dosage (TLED 912.81 ± 878.73 mg/d vs 503.78 ± 359.14 mg/d, P = 0.031), and had higher H&Y stage (2.33 ± 0.87 vs 1.41 ± 0.52, p = 0.013). However, logistic regression analysis didn't reveal the above factors as independent risk factors of ICD behaviors in our study. The incidence of ICDs behaviors in PD patients in our study is much lower than in western countries. ICD-PD group took higher dopamine agonists and higher total levodopa equivalent dosage, even though logistic regression analysis didn't reveal them as independent risk factors.